The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

Year Volume Issue First page
From through

  • Endocrine Care

    Usta Atmaca H, Akbas F

    Is Salusin-Alpha a New Marker of Cardiovascular Disease Risk in Hypothyroidism?

    Acta Endo (Buc) 2017 13(1): 53-59 doi: 10.4183/aeb.2017.53

    Introduction. Salusins are multifunctional endogenous peptides shown in human and rat tissues. Serum salusin α level is decreased in coronary artery disease and lack of salusin α enhances coronary atherosclerosis. Hypothyroidism is a chronic inflammatory disease that has a high risk of developing cardiovascular disease. Here we aimed to search the relationship of overt hypothyroidism and subclinical hypothyroidism with salusin α and other inflammatory markers, also the effect of L-thyroxine treatment on these findings. Material and Methods. 32 patients with overt hypothyroidism taking L-thyroxine treatment, 18 patients with subclinical hypothyroidism without treatment and 25 healthy patients as control group were included in the study. Serum salusin α, TNF α, sCRP, glucose, insulin and lipid levels were tested for all groups and results were evaluated with SPSS statistical analysis method. Results. HDL, sCRP, salusin mean values were statistically significantly different in all 3 groups. HDL level was statistically significantly higher in control group compared to treatment group. sCRP level was higher and salusin level was lower in both treatment and non-treatment hypothyroidism groups compared to control group. When treatment and non-treatment hypothyroidism groups were compared, there was no statistically significant difference for salusin α, but HDL level was high and insulin level was low statistically significant in treatment group. Conclusions. Salusin α that is shown to be protective for coronary artery disease and hypertension, is found to be significantly low in hypothyroidism, thus it is a marker that increases the cardiovascular disease risk in this specific patient group.
  • General Endocrinology

    Akbas F

    Protective Effect of Insulin Treatment on Early Renal Changes in Streptozotocin-Induced Diabetic Rats

    Acta Endo (Buc) 2018 14(2): 169-174 doi: 10.4183/aeb.2018.169

    Objectives. Chronic kidney disease is a progressive complication of diabetes mellitus (DM). This study aimed to analyse early renal changes in streptozotocin induced diabetic rats and demonstrate the effect of early treatment with insulin on kidney’s histology. Methods. 30 male-adult Sprague-Dawley rats were included in the study. Diabetes was induced in 24 of the rats by a single injection of 65 mg/kg streptozotocin dissolved in saline. 5 units/day NPH insulin injection was started to 10 rats as treatment group and 11 rats were followed untreated. 6 rats constituted the control group. Induction of diabetes failed in 3 animals and 3 untreated rats died during the study. After 21 days, all rats were sacrificed and their kidneys were removed to obtain histological sections to be evaluated by light microscopy. Results. Ten treated and 8 untreated diabetic rats and 6 healthy controls, totally 24 rats completed the study. There was a significant weight loss in treated and untreated diabetic groups and a weight gain in the control group (p<0.05). Final blood glucose levels were significantly higher in untreated diabetic group when compared to treated diabetic and control groups and higher in treated diabetic group when compared to control group. Histological analysis of kidney sections showed normal morphology in control group. Changes like increased mesangium, tubular atrophy and tubules with dilated lumen and irregular cell shapes were found in the untreated group whereas, glomerulus and mesangium showed similar morphology with control group with a few changes in tubules, in insulin-treated group. Conclusion. In DM, renal changes start at an early point and it is possible to prevent/delay those changes at this point with early intervention of insulin treatment.
  • Case Report

    Akbas ED, Ozalp Yuregir O, Anlas O, Ozcelik Z, Tolunay O

    A Novel Variant in Triple a Syndrome

    Acta Endo (Buc) 2021 17(3): 384-386 doi: 10.4183/aeb.2021.384

    Triple A syndrome is an autosomal recessive inherited multisystem disorder that was first described in 1978. Triple A syndrome has a high genotypic and phenotypic heterogeneity and has been linked with mutations in the AAAS gene, which has been identified on chromosome 12q13. A 14 years old male patient applied to outpatient clinic complaining of weakness and darkening of skin color since 4 months. On physical examination hyperpigmentation was observed on both the skin and mucosa. The morning cortisol level was 1.8 μg/dL and ACTH was >1250 ng/L. Schirmer test showed absence of tears. In the patient’s esophagoscopy, mucosal paleness and stenosis of the cardia were observed. Molecular genetic analysis of AAAS gene confirmed the diagnosis of triple A syndrome caused by homozygous mutation: c.1368_1372delGCTCA (p.Gln456HisfsTer38). This variant is considered to be a possible pathogenic because it causes a frame shift that changes the protein structure. As a result of the genetic analysis of the patient’s parents, the AAAS gene was detected as heterozygous in both parents for the c.1368_1372delGCTCA mutation. To the best of our knowledge, this is the first report of homozygous mutation: c.1368_1372delGCTCA (p.Gln456HisfsTer38).
  • Endocrine Care

    Usta Atmaca H, Akbas F

    The Effect of Short Term Alpha Lipoic Acid Administration on Adiponectin and Body Weight in Type 2 Diabetes Mellitus Patient

    Acta Endo (Buc) 2017 13(4): 461-466 doi: 10.4183/aeb.2017.461

    Background. Alpha lipoic acid (ALA) acts as essential co-factor for mitochondrion respiratory enzymes. It has an increasing importance in diabetic neuropathy treatment. Its positive effects on weight gain and metabolic parameters have also been discussed. In this study, we aimed to search for the effect of ALA on weight, appetite, adiponectin and metabolic parameters in type 2 diabetes mellitus patients. Methods. This study is designed as a randomised, double-blind, placebo controlled, prospective study. 23 type 2 diabetes mellitus patients with peripheral neuropathy (6 normal weight, 17 obese) and 21 normal weight control group were included in the study. Patients were given 600mg/day oral ALA for 6 weeks, added to their routine therapy. Body mass index (BMI), adiponectin, fasting plasma glucose, HbA1C, lipid parameters and CRP levels were tested before and after ALA treatment. Results were evaluated using SPSS 15.0 for Windows. Results. Adiponectin levels were statistically significantly lower and CRP levels were higher in diabetes group when compared to control group. Although ALA treatment caused a slight weight loss, it was not statistically significant. Appetite scores were decreased in the diabetes group but it did not cause statistically significant weight loss. There was no significant change in metabolic parameters or adiponectin after the treatment. Conclusions. 600mg/dL ALA treatment for 6 weeks did not favor for metabolic parameters in type 2 diabetes patients. This result might be due to the dose or the duration of the treatment, genetic predisposition or dietery habits. Trial of higher doses for long terms might be needed for recovery.